Results 241 to 250 of about 9,613,246 (402)

Graves’ disease and mental disorders

open access: yesJournal of Clinical & Translational Endocrinology, 2019
A. Fukao   +7 more
semanticscholar   +1 more source

Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
The co‐delivery of mRNAs encoding a CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21) via lipid nanoparticles enables effective localized immunotherapy. This strategy not only suppresses tumor progression but also enhances type 1 conventional dendritic cell (cDC1) differentiation and activates CD8+ T cells, thereby inducing robust ...
Tao Jiang   +14 more
wiley   +1 more source

Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines

open access: yesAdvanced Science, EarlyView.
This review offers a comprehensive overview of pharmaceutical nanotechnology strategies to address limitations associated with the complex material basis and relative mild therapeutic efficacy of Chinese herbal medicines, and summarizes the advantages of these strategies.
Jiameng Li   +11 more
wiley   +1 more source

Rare Autoimmune Pancytopenia Due to Graves Disease. [PDF]

open access: yesJCEM Case Rep
Wang AW, Mahajan G, Etra A, Saul SR.
europepmc   +1 more source

The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor‐Intrinsic PD‐1/c‐MET Signaling in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
In pancreatic ductal adenocarcinoma (PDAC), tumor‐intrinsic PD‐1 signaling activates the MET pathway, leading to the establishment of an immunosuppressive tumor microenvironment (TME). This MET‐driven signaling cascade promotes the selective accumulation of GITR+ regulatory T cells (Tregs), a highly immunosuppressive subset.
Jiande Han   +16 more
wiley   +1 more source

Graves' Disease: Is It Time for Targeted Therapy? A Narrative Review. [PDF]

open access: yesMedicina (Kaunas)
Viola N   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy